From the Da Vinci surgical system to Ion Robotic Bronchoscopy, Fosun, a “full-attendance” exhibitor for all eight CIIE editions, has successfully transformed cutting-edge global technologies into localized innovative products.

Eight years at the CIIE, cutting-edge innovations flourishing in China

In July this year, the Marie Upright Particle Therapy System received US Food and Drug Administration (FDA) approval, marking a revolutionary breakthrough in cancer treatment. Just three months later, it made its debut in China at Fosun Pharma’s booth at the 8th CIIE.

Similarly, back at the first CIIE in 2018, Fosun showcased the groundbreaking Da Vinci surgical system. In the years that followed, Fosun brought a series of cutting-edge global innovations, including CAR-T cell therapy product Yi Kai Da and the magnetic resonance image guided focused ultrasound brain therapy system (MRgFUS brain therapy system) to the CIIE and introduced them to a wider audience.

More importantly, beyond technology innovation, Intuitive Fosun’s headquarters stands as the largest integrated R&D, production, and training base of Intuitive Surgical in the Asia-Pacific region. It not only advances the localized R&D and production of cutting-edge medical devices, but also offers “integrated medical and educational” training for domestic healthcare professionals. To date, it has provided training to more than 15,000 medical professionals.

Original innovation, driven by unmet clinical needs

While continuously driving the translation of cutting-edge global innovations and advancing localized innovation, Fosun has also established innovative platforms spanning antibodies, antibody-drug conjugates (ADCs), small molecules, and cell therapies. By enhancing its original innovation capabilities, Fosun has consistently delivered groundbreaking achievements in the field of innovative drugs. Since 2019, Fosun Pharma has successfully brought 12 innovative drugs to market.

Among these is HANSIZHUANG, recognized as the world’s first of its kind.

As the world's first anti-PD-1 monoclonal antibody approved for first-line treatment of small cell lung cancer (SCLC), HANSIZHUANG has successively received regulatory approvals in the European Union, the United Kingdom, Indonesia, and other regions. It has also been granted orphan drug designation (ODD) by both the United States and European Commission.

In October this year, HANSIZHUANG became the world’s first perioperative (pre-/post-surgical) treatment regimen for gastric cancer in which an immunotherapy monotherapy replaces postoperative adjuvant chemotherapy, marking a major breakthrough in this field.

In addition, Fosun’s R&D pipeline demonstrates significant potential to address unmet clinical needs.

HLX43, which has gained the widespread attention in industry, shows strong potential to become a broad-spectrum anticancer drug. As an innovative PD-L1-targeting ADC, it has the dual benefits of immunotherapy and targeted ADC, thereby significantly reducing the side effects of cancer treatment while potentially covering a broader range of tumor types.

Another promising candidate, HLX22, is the world’s first anti-HER2-targeted therapy for gastric cancer to receive ODD approval from both the European Commission and the United States. As a novel epitope anti-HER2 monoclonal antibody, HLX22’s Phase III clinical trials have been approved by regulatory authorities in China, the United States, Japan, Australia, Germany, and South Korea, and the first patient has already been dosed globally.

These achievements reflect Fosun’s unwavering commitment to “prioritizing patient benefit above all else” and “addressing unmet clinical needs”.

“The one thing I always emphasize is ‘cure’. I always remind my team that innovation should be driven by unmet clinical needs.” Guo Guangchang, Chairman of Fosun International, remarked at the 3rd Pujiang Biopharmaceutical Original Innovation Conference 2025

Leveraging open innovation to build a world-class Chinese pharmaceutical company

With a global vision, profound global operations, global R&D, and breakthrough in original innovation, Fosun has embarked on a unique journey of “open innovation”.

“For Fosun, the core of globalization lies in innovation capability and value chain integration. By combining a global vision with deep local development, Fosun advances original innovation while pioneering a unique ‘integrated innovation’ approach.” Wang Qunbin, Co-Chairman of Fosun International, said at the CIIE

This strategic approach is driven both by the rapid advancement of global technologies and resource constraints within a single enterprise, as well as driven by the broad perspective brought about by globalization.

“Over the years, Fosun has fully embraced innovation transformation, following from the start an open and collaborative approach. We work hand in hand with scientists and leading innovation-driven companies globally, engaging deeply in partnerships and industry collaborations to build a more open innovation platform.” Chen Qiyu, Co-CEO of Fosun International, said at the 3rd Pujiang Biopharmaceutical Original Innovation Conference 2025

Fosun’s open innovation system enables better integration with academia, capital markets, enterprises, and policies, creating greater value and fostering original innovation. Through global cooperation, it also helps bring cutting-edge innovations to China, supporting the development of high-quality healthcare in China.

“Innovation is never a solo endeavor or something developed in isolation without regard for reality. It is achieved through the integration of resources and the synergy of capabilities. At this crucial juncture today, China’s pharmaceutical innovation is gaining increasing attention and recognition around the world. More than ever, we are convinced that original innovation is the only way forward for the industry, and open cooperation is the best way to accelerate innovation.” Guo Guangchang, Chairman of Fosun International, said at the 3rd Pujiang Biopharmaceutical Original Innovation Conference 2025